Phenserine

Phenserine ((-) -Eseroline phenylcarbamate) is a derivative of Physostigmine and is a potent, noncompetitive, long-acting and selective AChE inhibitor. Phenserine reduces β-amyloid precursor protein (APP) and β-amyloid peptide (Aβ) formation. Phenserine improves cognitive performance and attenuates the progression of Alzheimer's disease[1][2][3].

Product Specifications

CAS Number

[101246-66-6]

Product Name Alternative

(-) -Eseroline phenylcarbamate; (-) -Phenserine

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Amyloid-β; Cholinesterase (ChE)

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/phenserine.html

Purity

99.55

Solubility

DMSO : 200 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CN1[C@](N(C)CC2)([H])[C@]2(C)C3=C1C=CC(OC(NC4=CC=CC=C4)=O)=C3

Molecular Formula

C20H23N3O2

Molecular Weight

337.42

Precautions

H315, H319, H335

References & Citations

[1]Klein J. Phenserine. Expert Opin Investig Drugs. 2007 Jul;16 (7) :1087-97.|[2]Asuni AA, et al. Modulation of amyloid precursor protein expression reduces β-amyloid deposition in a mouse model. Ann Neurol. 2014 May;75 (5) :684-99.|[3]Janas AM, et al. The cholinesterase inhibitor, phenserine, improves Morris water maze performance of scopolamine-treated rats. Life Sci. 2005 Jan 21;76 (10) :1073-81.